Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study To Evaluate The Effect Of Hepatic Impairment On The Pharmacokinetics And Safety Of Crizotinib In Advanced Cancer Patients

NCT01576406 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01576406
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01576406 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study To Evaluate The Effect Of Hepatic Impairment On The Pharmacokinetics And Safety Of Crizotinib In Advanced Cancer Patients
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2012
Completion date
June 30, 2016
Enrollment
88 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer